DHT Holdings, Inc.

DHT Details

DHT Holdings, Inc. (NYSE: DHT) is a crude oil tanker company with its own fleet. DHT's fleet consists of 27 Very Large Crude Carriers (VLCC), out of which 12 vessels operate on time-charters and 15 vessels operate on voyage charters, with a total capacity of 8,363,707 deadweight tons (dwt) as of June 30, 2021. Time charter contracts and voyage charter contracts (operating in the spot market) are the two forms of contracts that generate revenue for the firm. DHT's fleet operates across the globe on various international routes, and its management companies are located in Monaco, Singapore, and Norway.

Share Repurchases: On July 01, 2021, DHT stated that between May 17, 2021, and June 07, 2021, the company bought back and cancelled 3,721,841 of its common shares, representing 2.2% of the outstanding shares, at an average price of USD 6.025.

Sale of DHT Condor: DHT announced the delivery of its DHT Condor fleet to its new owner on July 08, 2021, and expects to book a profit of roughly USD 1.5 million in Q3FY21 on the sale price of USD 30.25 million. The company initially signed the agreement to sell DHT condor in April 2021.

H1FY21 Results: The company reported a massive decline of 66.60% in shipping revenues to USD 152.92 million during H1FY21 (ending June 30, 2021) compared to USD 457.85 million during H1FY20, owing to a decline in both the tanker rates and the total revenue days. As a result, DHT reported a sharp decline in net income to USD 12.42 million during H1FY21 vs. USD 207.98 million during H1FY20. As of June 30, 2021, the company's cash and cash equivalents amounted to USD 52.24 million, and the total debt was USD 526.18 million.

Key Risks: The company's top five customers collectively accounted for 53% and 41% of the total revenues during H1FY21 and H1FY20, respectively. Excessive dependence on a few customers for business could hurt the company's financial standing in the long run.

Outlook: As of August 09, 2021, 64% of DHT's available VLCC days have already been booked for Q3FY21, at an average price of USD 22,100 / day on a discharge-to-discharge basis. DHT also plans to use the current weak freight market conditions to its benefit by carrying out dry dockings, scrubber installations, and ballast water treatment systems. As a result, it estimates its scheduled off-hire will range between 80 and 100 days in Q3FY21.

Valuation Methodology: EV/EBITDA Multiple Based Relative Valuation

(Analysis by Kalkine Group)

* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

DHT Daily Technical Chart (Source: REFINITIV)

Stock Recommendation: DHT's share price has increased by 9.93% in just one month and is currently at the higher band of the 52-week range of USD 4.52 to USD 6.84. The stock is currently trading above its 50 and 200 DMA levels, and its RSI Index is at 63.01. We have valued the stock using the EV/EBITDA multiple-based relative valuation methodology and arrived at a target price of USD 5.53. Considering the current market conditions, a sharp decline in top and bottom-line, associated risks, and the current valuation, we recommend a "Sell" rating on the stock at the current price of USD 5.98, up by 1.70% as of September 09, 2021, 12:51 PM ET.

* The reference data in this report has been partly sourced from REFINITIV.

* All forecasted figures and industry information have been taken from REFINITIV.

Biomerica, Inc.

BMRA Details

Biomerica, Inc. (NASDAQ: BMRA) is a biomedical technology company that develops, produces, and distributes innovative diagnostic and therapeutic devices to diagnose and treat chronic and gastrointestinal disorders. It also offers diagnostic test kits for COVID-19, dietary intolerances, and other esoteric tests. BMRA currently serves ~400 diagnostic customers, comprising ~75 overseas distributors, 40 local distributors, and several domestic hospitals and other clinical laboratories and institutes. The firm's products are sold in Europe, Asia, the United States, South America, and the Middle East.

Inching Towards Completion of Patient Enrollment for InFoods DGT: On August 30, 2021, BMRA stated that it intends to complete patient enrollment in its InFoods diagnostic-guided therapy (DGT), which is designed to relieve Irritable Bowel Syndrome (IBS) symptoms. The final patients in the trial are expected to finish therapy by the end of October 2021, after which the research data will be locked for final statistical analysis. Top-line trial findings demonstrating the efficacy of the InFoods IBS treatment are expected by the end of CY21.

Allowance for Patent to Treat Depression: On August 11, 2021, BMRA was granted a notice of approval by the Japanese Patent Office for a patent relating to a new treatment option for individuals suffering from depression. The patent is expected to enable physicians to discover patient-specific foods (such as salmon, milk, shrimp, broccoli, chickpeas, and so on) that, when eliminated from the patient's diet, may improve depressive symptoms.

FY21 Results: The company reported YoY growth of 7.57% in net sales to USD 7.20 million in FY21 (ended May 31, 2021) compared to USD 6.69 million in FY20, primarily due to an increase in sales of COVID-19 test kits. However, BMRA reported an increase in a net loss to USD 6.47 million in FY21 vs. USD 2.34 million in FY20, owing to an increase in selling, general and administrative (SG&A), and research and development (R&D) expenses. As of May 31, 2021, the company's cash and cash equivalents amounted to USD 4.20 million, with no outstanding debt.

Key Risks: BMRA's key distributor accounted for over 33% and 26% of its net consolidated sales during FY21 and FY20, respectively, as well as most of its accounts receivable balances. Excessive reliance on a single distributor for products could harm the company's financial health in the long run. Furthermore, the company relies on third-party contract research organizations (CROs), universities, or clinical sites (vendors) to monitor and execute clinical trials and manage data for its clinical programs.  Any failure on the contractual obligation by these third parties could harm its financials.

Valuation Methodology: EV/Sales Multiple Based Relative Valuation

(Analysis by Kalkine Group)

* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

BMRA Daily Technical Chart (Source: REFINITIV)

Stock Recommendation: BMRA's share price increased 17.38% in the past month and is currently leaning towards the lower band of the 52-week range of USD 3.30 to USD 8.15. The stock is currently trading between its 50 and 200 DMA levels, and its RSI Index is at 63.80. We have valued the stock using the EV/Sales multiple-based relative valuation methodology and arrived at a target price of USD 4.03. Considering the company's road to regulatory processes, negative bottom-line, current trading levels, and valuation, we recommend a "Sell" rating on the stock at the current price of USD 4.66, up 7.13% as of September 09, 2021, 10:17 AM ET.

* The reference data in this report has been partly sourced from REFINITIV.

*All forecasted figures and industry information have been taken from REFINITIV.                                   

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.